参考文献
[ 1 ] 　Wallis S,Macierewicz J, Shrestha BM. Behcet′s disease: Report of a case and review of the literature [ J ]. JNMA J NepalMed Assoc, 2006, 45 ( 164) : 3622365.
[ 2 ] 　McDonald DR, Lee C, Fowler RA, et al. Behcet′s disease [ J ].CMAJ, 2007, 176 ( 9) : 127321274.
[ 3 ] 　Niedzielska A, Chelminska K, Jaremin B. Beh?et′s disease2diagnostic difficulties [ J ]. Pol Arch Med Wewn, 2007, 117 ( 9 ) :4272429.
[ 4 ] 　Salas Cabrera R, SaguéLarrea J, Laurencio Mena A. Bechet′sdisease[ J ]. Case Report Arch Esp Urol, 2007, 60 ( 1) : 67268.
[ 5 ] 　Hirohata S. Histopathology of central nervous system lesions in Behcet′s disease[ J ]. J Neurol Sci, 2008, 267 ( 1 /2) : 41247.
[ 6 ] 　Ahn JK, Park YG. Human leukocyte antigen B27 and B51 double2positive Behcet uveitis [ J ]. Arch Ophthalmol, 2007, 125( 10) : 137521380.
[ 7 ] 　Amoura Z, GuillaumeM, Caillat2Zucman S, et al. Pathophysiology of Behcet′s disease [ J ]. Rev Med Interne, 2006, 27 ( 11 ) :8432853.
[ 8 ] 　Guillaume2Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon2alpha in the treatment of corticodependent uveitis of paediatric Behcet′s disease [ J ]. Rheumatology (Oxford) , 2007,46 ( 10) : 157021573.
[ 9 ] 　ThirionM,Miceli2Richard C, LabetoulleM, et al. Low dose interferon2alpha to treat Behcet′s disease [ J ]. Clin Exp Rheumatol,2007, 25 ( 5) : 791.
[ 10 ] 　TakamotoM, Kaburaki T, Numaga J, et al. Long2term infliximab treatment for Behcet′s disease [ J ]. Jpn J Ophthalmol, 2007, 51( 3) : 2392240.
[ 11 ] 　AccorintiM, Pirraglia MP, ParoliMP, et al. Infliximab treatment for ocular and extraocularmanifestations of Behcet′s disease[ J ].Jpn J Ophthalmol, 2007, 51 ( 3) : 1912193.
[ 12 ] 　HoumanMH, Hamzaoui K. Promising new therap ies for Behcet′sdisease[ J ]. Eur J InternMed, 2006, 17 ( 3) : 1632169.
[ 13 ] 　Pip itone N, Olivieri I, Cantini F, et al. New app roaches in the treatment of Adamantiades2Behcet′s disease [ J ]. Curr Op in Rheumatol, 2006, 18 ( 1) : 329.
[ 14 ] 　Krause I,Weinberger A. Behcet′s disease [ J ]. Curr Op in Rheumatol, 2008, 20 ( 1) : 82287.
[ 15 ] 　Hirohata S. Diagnosis and therapy forBehcet disease[ J ]. Nippon Naika Gakkai Zasshi, 2007, 96 ( 10) : 222022225.
[ 16 ] 　Yazici H, Fresko I, Yurdakul S. Beh?et′s syndrome: diseasemanifestations,management, and advances in treatment[ J ]. Nat Clin Pract Rheumatol, 2007, 3 ( 3) : 1482155.
[ 17 ] 　Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Op in Ophthalmol[ J ]. 2007, 18 ( 6) : 4812486.
[ 18 ] 　Evereklioglu C. The treatment schedule and historical namingp rocess of Beh?e t disease [ J ]. J Eur Acad Dermatol Venereol,2007, 21 ( 3) : 4272428.
[ 19 ] 　Rosenbaum JT. Biologics and Behcet′s: disease diversity and trial design[ J ]. Ocul Immunol Inflamm, 2007, 15 ( 2) : 61262.
[ 20 ] 　Yazici H, Fresko I, Yurdakul S. Beh?et′s syndrome: diseasemanifestations,management, and advances in treatment [ J ]. Nat Clin Pract Rheumatol, 2007, 3 ( 3) : 148255.
[ 21 ] 　Kilmartin DJ, Forrester JV, Dick AD. Tacrolimus ( FK506 ) in failed cyclosporin A therapy in endogenous posterior uveitis[ J ].Ocul Immunol Inflamm, 1998, 6 ( 2) : 1012109.
[ 22 ] 　IshiokaM,Ohno S,Nakamura S, et al. FK506 treatment of noninfectious uveitis[ J ]. Am J Ophthalmol, 1994, 118 ( 6) : 7232729.
[ 23 ] 　Kovacova E, Salmas J, Stenova E, et al. Behcet′s syndrome [ J ].Bratisl Lek Listy, 2005, 106 (12) : 3862389.

来源：医学综述 作者：李　媛